MedTrace Logo

Circulating miRNAs.

NCT01722851 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 255

Last updated 2025-07-08

No results posted yet for this study

Summary

To identify a panel of circulating miRNA markers which could help identify those breast cancer patients who are most likely to respond well to neoadjuvant and adjuvant chemotherapy, and indeed serve as an overall prognostic factor and stratify patients into risk categories which would further guide their management. Similarly, the investigators aim to identify a panel of circulating miRNA markers which could monitor patient's response to chemotherapy and hormonal therapies. Ideally a suitable panel of markers would show significant changes in expression level in good-responders whilst little or no change would be observed in miRNA expression in non-responders.

Conditions

  • Breast Cancer
  • Newly Diagnosed Breast Cancer
  • Recurrent Breast Cancer

Sponsors & Collaborators

  • Cancer Trials Ireland

    lead NETWORK

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2021-04-01
Completion
2021-12-31

Countries

  • Ireland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01722851 on ClinicalTrials.gov